Cytokinetics' Myqorzo Hits Dual Endpoints in HCM Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Cytokinetics reported that Myqorzo met both primary efficacy endpoints in the Phase 3 ACACIA trial for non‑obstructive hypertrophic cardiomyopathy, showing statistically significant improvements in heart‑failure symptoms and cardiovascular fitness.
- Myqorzo is already marketed for obstructive HCM, and the trial success expands its potential use to the non‑obstructive form of the disease.
- Analysts project peak annual sales of $5 billion for Myqorzo if approved, reflecting a major revenue boost for Cytokinetics.
Why it matters: Cytokinetics will add $5 billion in peak sales, while patients with non‑obstructive hypertrophic cardiomyopathy gain a new approved therapy, expanding the treatable HCM population and increasing insurer coverage options.
